Hutchmed's Sovleplenib Secures Second Orphan Status in the US; Shares Rise 5%

MT Newswires Live11-05

Hutchmed (China)'s (HKG:0013) Sovleplenib drug has received orphan drug designation in the U.S. to treat autoimmune hemolytic anemia, a rare condition in which the human immune system attacks its own red blood cells.

The biopharma company said the move by the US Food and Drug Administration follows the drug's late-October orphan status for primary immune thrombocytopenia, an autoimmune bleeding disorder, according to a Thursday Hong Kong bourse filing.

Sovleplenib is currently awaiting approval for sale and licensing in China.

Shares were last up 5% in morning trading on the HKEX.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment